OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS

• Published in: Retina (Philadelphia, Pa.) Vol. 35; no. 12; p. 2489
• Main Authors: Chhablani, Jay, Kozak, Igor, Pichi, Francesco, Chenworth, Megan, Berrocal, Maria H, Bedi, Rumneek, Singh, Rishi P, Wu, Lihteh, Meyerle, Catherine, Casella, Antonio Marcelo, Mansour, Ahmad, Bashshur, Ziad, Scorza, Antonella, Carrai, Paola, Nucci, Paolo, Arevalo, J Fernando
• Format: Journal Article
• Language: English
• Published: United States 01.12.2015
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab - administration & dosage; Central Serous Chorioretinopathy - complications; Central Serous Chorioretinopathy - drug therapy; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Female; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab - administration & dosage; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity
• ISSN: 1539-2864
• DOI: 10.1097/IAE.0000000000000655

To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and >3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.